Goldstein J, Hobbs H, Brown M. The online metabolic and molecular bases of inherited disease. Chapter 120. Familial hypercholesterolemia. http://ommbid.mhmedical.com/DOI:10.1036/ommbid.149.
Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, et al. European atherosclerosis society consensus panel on familial hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35:2146–57.PubMedWeb of ScienceGoogle Scholar
Daniels SR, Gidding SS, de Ferranti SD. National lipid association expert panel on familial hypercholesterolemia. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5(Suppl 3):S30–7.Web of ScienceCrossrefGoogle Scholar
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk. Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128(Suppl 5):S213–56.Google Scholar
Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011;218:272–80.Web of ScienceCrossrefGoogle Scholar
Myśliwiec M, Walczak M, Małecka-Tendera E, Dobrzańska A, Cybulska B, et al. Management of familial hypercholesterolemia in children and adolescents. Positionpaper of the Polish Lipid Expert Forum. J Clin Lipidol 2014;8:173–80.CrossrefGoogle Scholar
McNeal CJ, Wilson DP, Christou D, Bush RL, Shepherd LG, et al. The use of surrogate vascular markers in youth at risk for premature cardiovasculardisease. J Pediatr Endocrinol Metab 2009;22:195–211.Google Scholar
Guardamagna O, Restagno G, Rolfo E, Pederiva C, Martini S, et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 2009;155:199–204.CrossrefPubMedGoogle Scholar
Davis HR Jr, Pula KK, Alton KB, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001;50:1234–41.PubMedCrossrefGoogle Scholar
Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996;97:619–28.Google Scholar
McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002;51:715–21.PubMedCrossrefGoogle Scholar
Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005;116:682–8.CrossrefPubMedGoogle Scholar
Kusters DM, Hutten BA, McCrindle BW, Cassiman D, Francis GA, et al. Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. J Clin Lipidol 2013;7:408–13.CrossrefWeb of SciencePubMedGoogle Scholar
Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. J Am Med Assoc 2014;312:1055–7.CrossrefWeb of ScienceGoogle Scholar
O’Gorman CS, Higgins MF, O’Neill MB. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr Cardiol 2009;30:482–9.CrossrefWeb of SciencePubMedGoogle Scholar
van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52:1421–9.PubMedCrossrefWeb of ScienceGoogle Scholar
Yeste D, Chacon P, Clemente M, Albisu MA, Gussinye M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 2009;22:487–92.PubMedGoogle Scholar
Araujo MB, Botto PM, Mazza CS. Use of ezetimibe in the treatment of familial hypercholesterolemia in children and adolescents. AnPediatr (Barc) 2012;77:37–42.Google Scholar
Kusters DM, Caceres M, Coll M, Cuffie C, Gagné C, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr 2015;166:1377–84.PubMedCrossrefGoogle Scholar
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409–15.PubMedCrossrefGoogle Scholar
Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, et al. Atherosclerosis: recent trials, new targets and future directions. Int J Cardiol 2015;192:72–81.Web of SciencePubMedCrossrefGoogle Scholar
Tyroler HA. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol 1984;54:14C–19C.Google Scholar
Magnussen CG, Venn A, Thomson R, Juonala M, Srinivasan SR, et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol 2009;53:860–9.Web of ScienceGoogle Scholar
Kologlu T, Ucar SK, Levent E, Akcay YD, Coker M, et al. Chitotriosidase as a possible marker of clinically evidenced atherosclerosis in dyslipidemic children. J Pediatr Endocrinol Metab 2014;27:701–8.Web of SciencePubMedGoogle Scholar
About the article
Published Online: 2016-10-08
Published in Print: 2016-11-01
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.